semaglutide

Gilead and Novo plot next steps after trial data from NASH combo
Gilead and Novo plot next steps after trial data from NASH combo
Pharmaforum
Gilead Sciences
Novo Nordisk
NASH
clinical trials
semaglutide
cilofexor
firsocostat
Flag link:
Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow
Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow
Endpoints
Novo Nordisk
earnings
NASH
semaglutide
breakthrough therapy
FDA
Flag link:
Novo adds weight to its obesity goals
Novo adds weight to its obesity goals
EP Vantage
Novo Nordisk
semaglutide
obesity
Flag link:
Novo launches type 2 diabetes pill in UK after NICE waives review
Novo launches type 2 diabetes pill in UK after NICE waives review
Pharmaforum
Novo Nordisk
UK
type 2 diabetes
diabetes
Rybelsus
semaglutide
NICE
Flag link:
Novo Nordisk axes experimental obesity drugs after success with later-stage meds
Novo Nordisk axes experimental obesity drugs after success with later-stage meds
Fierce Biotech
Novo Nordisk
obesity
semaglutide
Flag link:
Novo's diabetes drug also appears to work in NASH
Novo's diabetes drug also appears to work in NASH
BioPharma Dive
Novo Nordisk
NASH
semaglutide
Flag link:
Mark Your Calendar For These September PDUFA Dates
Mark Your Calendar For These September PDUFA Dates
Yahoo/Benzinga
FDA
Roche
Celgene
Tecentriq
Xeris Pharmaceuticals
Gvoke
Ardelyx
tenapanor
Merck
Pifeltro
Delstrigo
Novo Nordisk
semaglutide
JNJ
Genmab
daratumumab
Invokana
Flag link:
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Fierce Pharma
Eli Lilly
ADA
diabetes
heart attack
stroke
Trulicity
Novo Nordisk
semaglutide
Flag link:
Novo Nordisk seeks FDA nod for oral diabetes pill
Novo Nordisk seeks FDA nod for oral diabetes pill
Drug Delivery Business News
Novo Nordisk
FDA
semaglutide
diabetes
Flag link:
Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?
Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?
Fierce Pharma
Novo Nordisk
diabetes
Teva Pharmaceutical
Victoza
semaglutide
Flag link:
Novo bets on swift FDA review for oral diabetes drug semaglutide
Novo bets on swift FDA review for oral diabetes drug semaglutide
Endpoints
Novo Nordisk
earnings
semaglutide
FDA
Flag link:
The 20 Hottest Pipeline Drugs to Watch in 2019
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor
Flag link:
3 Biotechs With Potential Blockbusters Near the Finish Line
3 Biotechs With Potential Blockbusters Near the Finish Line
Motley Fool
Vertex Pharmaceuticals
VX-659 + tezacaftor + ivacaftor
Celgene
JCAR017
Novo Nordisk
semaglutide
Flag link:
Novo Nordisk’s Semaglutide Hits Mark in Type 2 Diabetes Trial
Novo Nordisk’s Semaglutide Hits Mark in Type 2 Diabetes Trial
BioSpace
Novo Nordisk
clinical trials
semaglutide
type 2 diabetes
Flag link:
Novo Nordisk trumpets more Januvia-topping data for oral semaglutide
Novo Nordisk trumpets more Januvia-topping data for oral semaglutide
Fierce Pharma
Novo Nordisk
semaglutide
Merck
Januvia
HbA1C
Flag link:
Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia
Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia
Fierce Pharma
Novo Nordisk
diabetes
semaglutide
Victoza
Merck
Januvia
Flag link:
Novo Nordisk's oral diabetes drug beats Jardiance in study
Novo Nordisk's oral diabetes drug beats Jardiance in study
Yahoo/Reuters
diabetes
Novo Nordisk
semaglutide
Jardiance
Eli Lilly
Flag link:
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Fierce Pharma
Novo Nordisk
obesity
semaglutide
Flag link:
In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug
In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug
Endpoints
Novo Nordisk
Eli Lilly
diabetes
clinical trials
semaglutide
Trulicity
Flag link:
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Fierce Pharma
Novo Nordisk
semaglutide
Eli Lilly
Ozempic
Trulicity
Flag link:

Pages